Skip to content

Marlou

Active Private limited companyfounded 2019active for 7 yearsBerkenlaan 8, 2970 SchildeKBO/BCE: BE 0723.433.126

Lifetime

7 annual accounts with figures on one time axis
peak of €682,440 in 2025
€682,440▲ 5.8%
peak of €489,709 in 2025
€489,709▲ 5.0%
peak of €510,169 in 2025
€510,169▲ 25×
€72,108▼ 85.0%
Board2 names since 2019
2 directors and 1 other
Documentsfilings and deeds
30-06-202631 days before the deadline
2025micro format
Equity from €20,460 to €510,169Debts from €481,415 to €72,108Investments €101,556

Key points

from the 2025 annual accounts

Equity

€510,169 ▲ 25×
€20,5002024€510,0002025

Equity rose in 2025 from €20,460 to €510,169.

Turnover

≈ €1.0m estimated

The micro format states no turnover.

Investments

€101,556 19.0 times depreciation
202320242025

Green is investment, beige is depreciation. Land and buildings stand 461.3% higher than in 2024.

Liquidity

5.28 was 0.82 in 2024

Short-term debts fell from €481,415 to €72,108.

Filings

7 annual accounts since 2019
AprilJune31 JulyOctober202020222024

The last five annual accounts were filed 1 to 31 days before the end of the period.

Position in the sector

€489,709

Higher net result than 95% of companies in human health. The sector median is €59,520, over 21,372 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 6,787 companies had the same profile as Marlou has now. Each dot stands for 17 companies, two years later.

96.7%
were still trading
2.7%
stopped another way
0.6%
went bankrupt
  • Small
  • 5 to 10 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 6,787 companies, not a prediction for Marlou. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 20-03-2019
Director, since 20-03-2019
  • 93 sharesdeed of 25-03-2019
  • 93 sharesdeed of 25-03-2019
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0723433126
Company renamed to Marlou (director) and (director) change roles · General meeting of 31-01-2023 · Gazette deed
Incorporation Founding capital of €18,600, 186 shares · Founded by ; · (manager) and (manager) appointed · published on 25-03-2019 · Gazette deed
First establishment Dr.Herten & Dr.Van Gestel, Berkenlaan 8, Schilde
All 17 events

Comparable companies

same main activity, similar in size and age
Company
Marlou Schilde €582,277 €682,440 87.6% -
CASTORIS Lille €557,254 €721,621 0.0% -
Celvia Zoersel €637,934 €678,278 3.2% -
Dr. Jef Huyskens, Radioloog Antwerp €531,560 €747,453 0.0% -
SB RAD Brasschaat €537,855 €757,020 8.4% -
Dr. Liesbeth Wellens Balen €529,504 €705,953 20.5% -
DR. GILLARDIN PATRICK Leuven €574,549 €692,137 3.2% -

These companies have the same main activity as Marlou: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €530,000 and €638,000, founded between 2018 and 2020.

Official details

Source: KBO
Status
Active since 21-03-2019Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.288.146.7572970 Schilde, since 21-03-2019
Financial year end
31 December
Peppol
Reachable since 14-12-2025
Company details

Annual accounts 2025

€582,277▲ 16.0%
Filing
Filed on 30-06-2026, 31 days before the end of the filing period
Financials

Insights on Marlou

Marlou files the micro format. That format states no turnover. The gross margin rose from €187,229 in 2019 to €682,440 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Marlou

What is the company number of Marlou?
The company number of Marlou is 0723.433.126. The VAT number is the same number with BE in front: BE 0723.433.126.
Where is Marlou based?
The registered office is at Berkenlaan 8, 2970 Schilde.Company details
What does Marlou do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of Marlou?
Marlou is a private limited company (BV).
When was Marlou founded?
Marlou was founded on 21-03-2019.
Is Marlou still active?
Yes, Marlou is an active enterprise in the KBO register.
What is the turnover of Marlou?
The turnover in financial year 2025 is about €1.0m. This figure is estimated from the gross margin of €682,440 and 31 comparable companies (NACE 86220). It probably lies between €910,000 and €1.4m.Financials
Is Marlou profitable?
In financial year 2025, Marlou made a profit of €489,709.
Where can I find the annual accounts of Marlou?
Marlou filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Marlou due?
Marlou must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.